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Background: All-trans retinoid acid (ATRA) has been proven to skew Regulatory T cell-T helper 17 cell (Treg-Th17)
balance toward Treg in vitro, favoring graft acceptance. However, its in vivo effect after solid organ transplantation is
under investigation.
Results: BALB/c mice were given orthotopic corneal grafts from C57BL/6 donors, and recipient mice were administered
with ATRA, TGF-β, and the combination of both agents for 8 weeks after surgery. We found that a mixed treatment of
ATRA and TGF-β significantly promoted graft survival. Moreover, with the presence of TGF-β, ATRA upregulated CD4
+CD25+Foxp3+Treg cells and suppressed Th17 cells in the blood, spleen and draining lymph nodes of recipient mice, as
well as enhanced the Foxp3 expression and inhibited the RORγt expression in grafts and peripheral blood mononuclear
cells (PBMCs). Simultaneously, increased number of Foxp3+ cells and decreased number of IL-17+ cells in conjunctiva
were found in recipients with mixed treatment, along with reduced IL-17 level in serum and aqueous humor and
increased IL-10 level in aqueous humor. Tregs isolated from recipient mice treated with ATRA + TGF-β presented the
strongest suppressive activity in vitro.
Conclusions: Combined application of ATRA and TGF-β may shift the Th17-Treg balance toward Tregs, hence facilitating
the induction of immunological tolerance after allogenic corneal transplantation and representing a potential therapeutic
approach in the treatment of posttransplant rejection.
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Corneal disease, one of the leading causes of blindness
in China [1], requires corneal transplantation to restore
visual function in the majority of cases [2]. Although
immune privilege of corneal allografts endowed a higher
success rate of corneal transplantation than other
solid organ transplantation, immunological rejection
is still the major cause of graft failure after penetrating
keratoplasty [3,4].
CD4+CD25+Foxp3+Regulatory T cells (Treg), an import-
ant regulator in maintaining immune homeostasis, play a
crucial role in protecting individuals from graft rejection* Correspondence: angela_le1977@163.com
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unless otherwise stated.[5]. In light of this, these cells are now considered an
important target for generating tolerance to solid organ
transplants. However, it has been found that Tregs can be
subverted by inflammatory conditions and converted into
interleukin-17 (IL-17)-producing T helper cells (Th17) [6].
Treg and Th17 cells share a common requirement for
TGF-β in their differentiation, despite expressing dis-
tinct transcriptional regulators (Foxp3 versus RORγt,
respectively) and demonstrating opposing functions.
IL-17 is involved in the allograft rejection, and IL-17
antagonism prolongs graft survival [7,8]. The balance
of Treg-Th17 axis and its shift toward the stabilization of
Treg populations are one of the key points in maintaining
graft tolerance.
Some cytokines or interventions have been proven to
alter the Treg-Th17 balance. Either IL-6 or IL-27 could
inhibit Treg induction and promote IL-17 production,
shifting the balance of the Treg-Th17 axis toward Th17This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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factor 4 is beneficial in maintaining the Foxp3 expression,
which is crucial for the immunoregulatory function of
Tregs, and suppressing the production of IL-17 and IL-21,
as well as prohibiting the activation of retinoic acid
receptor-related orphan receptor (ROR) γt, the hallmark
of Th17 activation [11].
Recent studies show that the key metabolite of vitamin
A, all-trans retinoid acid (ATRA), potentiates TGF-β-
dependent Treg induction, while it reciprocally inhibits
pro-inflammatory Th17 differentiation ex vivo [12,13].
Disrupted ATRA metabolism or signaling causes altered
homing or impaired functional differentiation of the lym-
phocytes [14]. ATRA has been demonstrated to sustain the
stability of Foxp3 expression and suppress RORγt expres-
sion in vitro, maintaining the function of Tregs and inhibit-
ing Th17 development [15,16]. However, the effect ofFigure 1 Graft survival curve. Each group contained at least 30 recipient
postoperative. The curve represents the average survival rate of each group
ATRA alone or the combination of ATRA and TGF-β had a modestly higher
Nevertheless, a single administration of TGF-β did not promote graft surviv
(35–56 days), the survival rate of grafts treated with either ATRA or TGF-β sol
vs control: 48%). A mixed administration of ATRA and TGF-β further promotedATRA on another pivotal transcriptional factor for the
generation of Th17 cells, RORα, remains unclear.
Until now, regulation of the reciprocal differentiation of
Tregs and Th17 cells has been investigated mainly in vitro.
There have been few studies conducted on in vivo regula-
tion. Moreover, few reports have been published to explore
the effect of ATRA on Treg-Th17 balance after allogenic
organ or tissue transplantation. Hence, we conducted this
study to explore the effect of ATRA on Treg-Th17 balance
after allogenic corneal transplantation and determine its cor-
relation with the outcome of cornea grafts in recipient mice.
Results
A mixed treatment of ATRA and TGF-β promotes graft
survival
During the follow-up, 9 mice died unexpectedly, two in
ATRA group (at 8d and 35d respectively), one in TGF-βmice at 14 days, 20 mice at 28 days and 10 mice at 56 days
. At the early time point (10–21 days), the grafts treated with either
survival rate (100%) than those treated with a control solution (82%).
al at an early stage following surgery. In contrast, at a late time point
ely was significantly higher than controls (ATRA: 65% and TGF-β: 60%
graft survival rate to 82%.
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and 42d respectively), two in control group (at 8d and 28d
respectively) and one in synergistic group (at 39d). The
same number of recipient mice was recruited. So a total of
159 mice were censored, with an overall graft survival rate
of 71%. The recipient mice treated with the combination of
ATRA and TGF-β presented a graft acceptance rate of 82%
at the end of the 8-week follow-up, which is significantly
higher than those treated with ATRA alone (P = 0.042),
TGF-β alone (P = 0.023) and a control solution (P = 0.008).
Meanwhile, it didn’t have significant differences compared
with syngeneic grafts (P = 0.074), as shown in Figure 1.Figure 2 Percentage of CD4+CD25+Foxp3+Treg cells in blood, spleen
administration of either ATRA or TGF-β promoted the level of CD4+CD25+F
compared with those treated with a control solution. A mixed administrati
postoperative, the level of CD4+CD25+Foxp3+ Treg cells in spleen and lymp
ATRA or TGF-β. Nevertheless, the synergistic effect was not found in those wi
error and are representative of at least three independent experiments. (B) Re
CD3 + CD4 + cells from the blood, spleen and LN in recipient mice. * P < 0.05A mixed treatment of ATRA and TGF-β upregulates
CD4+CD25+Foxp3+Treg cells in recipient mice
The percentage of CD4+CD25+Foxp3+Treg cells in blood
was significantly increased at 2wks in recipients treated
with ATRA, TGF-β and the combination of both agents
(P = 0.020, 0.039 and 0.040, respectively). However,
such effects were not found at 4wks and 8wks. Single
treatment of either ATRA or TGF-β promoted Treg
level in spleen at 2wks and 8wks (ATRA: P = 0.004
and 0.002, TGF-β: P = 0.001 and 0.025, respectively).
Compared to recipients with a single administration,
mixed treatment further enhanced Treg in the spleenand draining lymph nodes. (A) At 2wks postoperative, a single
oxp3+Treg cells in peripheral blood, spleen and draining lymph nodes,
on of ATRA and TGF-β further enhanced the level of Tregs. At 8wks
h nodes was increased in those with a single administration of either
th a mixed treatment. Data are presented as the mean value ± standard
presentative flow cytometric figures of Foxp3 and CD25 expression on
, ** P < 0.01, ***P < 0.001.
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Nevertheless, the synergistic effect was not found at
4wks and 8wks. The results of Treg level in the lymph
nodes were similar to those in the spleen, as shown
in Figure 2.
A mixed treatment of ATRA and TGF-β suppresses Th17
cells in recipient mice
The percentage of Th17 cells in blood was reduced
significantly in recipients with a single administration
of either ATRA or TGF-β at 2wks (ATRA: P = 0.011,
TGF-β: P = 0.016). At 4wks, recipients with a mixed
treatment also presented a significantly lower percentageFigure 3 Percentage of Th17 cells in blood, spleen and draining lymph
with a single administration of either ATRA or TGF-β was significantly lower th
two agents could further suppress Th17 cells in lymph nodes at 2wks and 8 w
representative of at least three independent experiments. (B) Representative f
from the blood, spleen and LN in recipient mice. * P < 0.05, ** P < 0.01, ***P <of Th17 cells in the blood (ATRA: P <0.001, TGF-β:
P = 0.001, mixed: P <0.001). The level of Th17 cells in
the spleen was significantly higher in the control
group than in the other four groups at 2wks (P <0.001).
However, no significant differences were found
among the five groups at 4wks and 8wks. A single
treatment of either ATRA or TGF-β caused a signifi-
cant reduction of Th17 cell levels in draining lymph
nodes at 2wks and 8wks, compared with control re-
cipients (both P <0.001). Moreover, a mixed treat-
ment of ATRA and TGF-β further decreased the
percentage of Th17 cells in the lymph nodes, as shown
in Figure 3.nodes. (A) At 2wks postoperative, the level of Th17 cells in recipients
an those treated with a control solution. A mixed treatment of these
ks. Data are presented as the mean value ± standard error and are
low cytometric figures of IL-17 and CD8 expression on CD3 + CD4+ cells
0.001.
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Foxp3+ cells and decreases IL-17+ cells in conjunctiva,
as well as prohibits inflammation in the grafts
At 2wks after transplantation, no inflammatory infiltrates
and graft edema were found in all groups (Figure 4, left
column). For recipient mice treated with either ATRA
or TGF-β, a few foxp3+ cells could be found in the
conjunctiva (Figure 5, left column). At 4wks, obvious
inflammatory infiltration in the graft stroma and graft
edema was visible in the control solution-treated recipients.
A smaller amount of inflammatory infiltration could be
found in the TGF-β-treated recipients. However, neither
grafts with a mixed treatment of ATRA and TGF-β nor
syngeneic grafts presented inflammatory infiltration and
graft edema (Figure 4, middle column). Foxp3+ cells could
be found in the conjunctiva of recipients treated with
ATRA, TGF-β or a mixture of both, while IL-17+ cells were
visible in the conjunctiva of the control solution-
treated recipients (Figure 5, middle column). At 8wks,
more or less inflammatory cells were infiltrated in the
graft treated with ATRA, TGF-β and control solution.
In contrast, the lamellar structure of the stromal collagen
was clearly visible in grafts with a mixed treatment,
despite epithelium proliferation (Figure 4, right column).
The immunofluorescence staining for conjunctivaFigure 4 Histology assessment of allogeneic grafts. At 2wks after trans
all groups. At 4wks, obvious inflammatory infiltration in the graft stroma an
A smaller amount of inflammatory infiltration could be found in the TGF-β
ATRA and TGF-β nor syngeneic grafts presented inflammatory infiltration and
the graft treated with ATRA, TGF-β and control solution. In contrast, the lame
treatment, despite epithelium proliferation. (Hematoxylin - eosin staining, × 2presented similar results as compared with those taken at
4wks postoperative (Figure 5, right column). The quantita-
tive analysis of inflammatory cells, Foxp3+ cells and IL-17
+ cells in the tissue is presented in Table 1.
A mixed treatment of ATRA and TGF-β increases the
Foxp3 expression and inhibits the RORγt expression in
grafts and PBMCs
At 2wks postoperative, the Foxp3 gene expression in
PBMCs was significantly higher in recipients treated
with either ATRA or the combination of ATRA and
TGF-β (P = 0.023), while at 4wks postoperative, the
Foxp3 expression in the cornea grafts increased sig-
nificantly in these two groups (P = 0.012). A signifi-
cantly lower RORγt expression in the PBMCs was
found in those receiving a mixed treatment at 2wks
postoperative (P = 0.042), while the RORγt expression
in the grafts was significantly lower in recipients
treated with either TGF-β or the combination of
ATRA and TGF-β at 4wks (P = 0.025). The RORα
expression in PBMCs was significantly higher in re-
cipients treated with ATRA at 2wks (P = 0.029). As
for RORα expression in grafts, no statistical signifi-
cance was found among the five groups, as shown in
Figure 6.plantation, no inflammatory infiltrates and graft edema were found in
d graft edema as well was visible in control solution-treated recipients.
-treated recipients. However, neither grafts with mixed treatment of
graft edema. At 8wks, more or less inflammatory cells were infiltrated in
llar structure of stromal collagen was clearly visible in grafts with a mixed
00).
Figure 5 Immunostaining of Foxp3+ cells and IL-17+ cells in recipients’ conjunctiva. A few foxp3+ cells could be found in the conjunctiva
of recipients treated with either ATRA or TGF-β at 2wks postsurgery. At 4wks and 8wks, Foxp3+ cells could be found in the conjunctiva of recipients
treated with either ATRA or TGF-β, while IL-17+ cells were visible in control solution-treated ones. Recipients with a mixed treatment presented more
Foxp3+ cells compared with those with a single treatment. Foxp3+ cells were stained as red and IL-17+ cells were green.
Table 1 Quantitative analysis of inflammatory cells, Foxp3+ cells and IL-17+ cells in grafts and conjunctiva in recipient mice
(cells/μm2) ATRA TGF-β ATRA + TGF-β Control Syngeneic P value
Inflammatory cells
2w 0 0 0 14.9 ± 18.72 0 0.132
4w 496.1 ± 68.4 891.4 ± 80.9 93.2 ± 45.2 1842.5 ± 68.4 0 <0.001
8w 1356.0 ± 260.7 1843.2 ± 252.8 152.9 ± 52.9 1872.4 ± 106.3 29.8 ± 6.5 <0.001
Foxp3+ cells
2w 21.9 ± 1.4 4.9 ± 0.6 16.7 ± 5.4 10.3 ± 2.7 25.6 ± 1.8 <0.001
4w 24.7 ± 0.6 29.4 ± 6.5 47.9 ± 2.2 22.2 ± 9.1 44.9 ± 6.7 0.004
8w 32.5 ± 5.1 36.9 ± 4.3 52.6 ± 4.8 25.5 ± 6.2 36.4 ± 7.3 0.001
IL-17+ cells
2w 5.5 ± 1.0 8.5 ± 0.8 2.4 ± 0.4 8.1 ± 0.6 3.3 ± 1.2 0.017
4w 3.5 ± 2.3 3.5 ± 0.2 5.1 ± 1.6 46.7 ± 12.4 5.1 ± 0.8 <0.001
8w 7.9 ± 1.7 8.7 ± 1.2 2.9 ± 1.3 50.0 ± 4.8 3.8 ± 1.1 <0.001
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Figure 6 Gene expression of Foxp3, RORγt and RORα in the grafts and PBMCs. At 2wks postsurgery, a mixed treatment of ATRA and TGF-β
significantly promoted the Foxp3 expression in PBMCs and suppressed the RORγt expression as well. At 4wks, the Foxp3 expression increased
significantly in the allogeneic grafts either with a mixed treatment or ATRA alone, and the reduced expression of RORγt was likewise found in
these two groups. At each time point, each group contained at least five corneas and three blood samples. Data are presented as the mean
value ± standard error and are representative of at least two independent experiments. * P < 0.05.
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level in the serum and aqueous humor and increases the
IL-10 level in the aqueous humor
Figure 7 showed that at 2wks postoperative, the serous level
of IL-10 was (50.1 ± 4.6) pg/ml in the recipients treated
with a control solution, which is significantly lower than
the other four groups (F = 8.063, P = 0.011). At 4wks, thecombined treatment of ATRA and TGF-β significantly in-
creased the level of IL-10 in the aqueous humor as com-
pared with the other groups (F = 7.505, P = 0.002). At 2wks
and 4wks, the serous level of IL-17 was (1.8 ± 0.7) pg/ml
and (2.1 ± 1.3) pg/ml in recipients with a mixed treatment,
which is significantly lower than recipients with any other
treatments (F = 5.887 and 6.453, P = 0.005 and 0.004). At
Figure 7 The concentration of IL-10 and IL-17 in the serum and aqueous humor. A mixed treatment of ATRA and TGF-β reduced the serous
level of IL-17 in serum at 2wks and 4wks and decreased the concentration of IL-17 in the aqueous humor at 4wks and 8wks. Meanwhile, a mixed
treatment increased the IL-10 level in the aqueous humor at 4wks. At each time point, each group contained at least three samples of serum and
five samples of aqueous humor. Data are presented as the mean value ± standard error and are representative of at least two independent experiments.
* P < 0.05, ** P < 0.01, ***P < 0.001.
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humor was far higher in the recipients treated with a con-
trol solution than the other groups (F = 682.622 and
248.868, both P < 0.001).
A mixed treatment of ATRA and TGF-β increases the
suppressive activity of CD4 + CD25 + Foxp3+ Tregs in vitro
Figure 8 illustrated that the suppressive rate of Tregs
isolated from recipient mice treated with a control solu-
tion was (50.1 ± 6.1)%. Administration of either ATRA
or TGF-β increased the suppressive rate to (67.9 ± 8.2)%
and (69.9 ± 13.4)%, respectively. A mixed treatment of
both agents could further increase the suppressive rate
to (86.1 ± 3.0)%, which was significantly higher than
the control group (F = 10.842, P = 0.002).
Discussion
Th17 cells, which recruit monocytes and neutrophils by the
secretion of IL-17 and suppress the expansion of regulatoryT cells, have been implicated to be predominantly involved
in the acute phase of allograft rejection [8,17,18], especially
within 5–14 days. This study confirmed that Th17 cells
were detrimental to allogeneic graft survival. Moreover, we
not only found the enhancement of Th17 cells in peripheral
blood and draining lymph nodes at the early stage of
the rejection process after corneal transplantation, but
also identified an increased number of IL-17-positive
cells in conjunctiva, enhanced expression of RORγt in
cornea grafts and an elevated level of IL-17 in the
aqueous humor at the late stage of rejection process,
which has not been reported by previous studies. We
assumed that the disparities might be attributed to two
reasons. First, unlike other solid organ transplantation,
immunological rejection after allogeneic corneal trans-
plantation does not affect the survival of the recipients,
which is conducive to observing the long-term dynamic
changes of Th17 cells. Second, the activated Th17 cells
might take some time to migrate from peripheral
Figure 8 The suppressive activity of CD4 + CD25 + Foxp3+ T cells
isolated from recipient mice. A single treatment of either ATRA or
TGF-β could enhance the suppressive activity of CD4 + CD25 +
Foxp3+ T cells in vitro. A mixed treatment of ATRA and TGF-β
could further increase the suppressive activity. Each group contained
five samples. Data are presented as the mean value ± standard error
and are representative of at least three independent experiments.
* P < 0.05, ***P < 0.001.
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into cornea graft, since cornea is absent of blood and
lymphatic vessels.
Although CD4 + CD25 + Foxp3 + Tregs have strong
immunosuppressive potency, they are present in very
low numbers in a normal host and have an anergic
phenotype. The upregulation of CD4 +CD25 + Foxp3 +
Tregs induced by certain agents, such as rapamycin and
IL-2, has been proven to protect the allogeneic graft and
prolong graft survival [19]. Nevertheless, the expression of
Foxp3 is unstable and will be down-regulated in an
IL-6-rich, Th17-promoting environment. When such
Treg ‘deprogramming’ occurs, Tregs fail to exert their
original immunoinhibitory role [20,21] and may convert
into competent Foxp3- effector T cells, which up-regulate
the RORγt expression [11]. Inflammation-dampening
strategies, particularly manipulating the inflammation
occurring in the graft and draining lymph nodes,
may guide the host immunity from an adverse effect
toward tissue-protective phenotypes. Therefore, shifting
the Th17-Treg profile toward Tregs and maintaining the
Foxp3 expression is crucial in protecting the allografts and
achieving graft acceptance.
It has been shown that ATRA is one of potential
therapeutic agents capable of skewing the Treg–Th17
axis away from a Th17 response. Retinoic acid was first
identified as a potential regulator of T cell homing to the
intestinal tract, with intestinal dendritic cells being
unique in their production of retinoic acid [22]. A novel
role of retinoic acid in the regulation of the Th17–Treg
axis, inhibiting the development of Th17 cells by splenic
dendritic cells, was discovered by Mucida et al. [23]Recent studies have demonstrated that the reduction
in IL-17 was accompanied by a reduction in the
RORγt expression in response to ATRA [24]. Furthermore,
Tregs expanded with ATRA are resistant to the inhibitory
effects of IL-6 on the Foxp3 expression and prevent
Th17 conversion [15], thus stabilizing the Tregs population
and function.
However, ATRA is not sufficient to convert mouse
naïve T cells undergoing activation into Foxp3+ T cells.
Many studies have confirmed that the TGF-β signal is
additionally required for a reliable expression of Foxp3
in T cells in vitro [12,23,24]. Some findings suggested
that ATRA enhanced TGF-β signaling by increasing the
expression and phosphorylation of Smad3 and also
inhibited the expression of IL-6 receptor α chain [24,25].
Other findings suggested that ATRA reduced the STAT6
binding to the Foxp3 promoter or indirectly relieved
inhibition of the TGF-β-mediated Foxp3 expression
from cytokine-producing CD4+CD44hi T cells and finally
enhanced the Foxp3 expression [26,27]. A few in vivo
studies also confirmed that with the presence of TGF-β,
ATRA promoted Treg conversion and inhibited Th17
induction [18,28].
The combined administration of ATRA and TGF-β
has been proven to attenuate heart, liver and trachea
rejection [18,29,30]. The effect was attributed, at least
partially, to the shifted balance of the Th17-Treg axis,
meaning for the conversion of the CD4 + Foxp3 + Tregs
and suppressed induction of the Th17 cells. This study
found that with the presence of TGF-β, ATRA could
maximally promote allogeneic graft survival. In contrast,
the treatment of ATRA alone could not entirely mitigate
graft rejection. Previous studies have demonstrated that
without TGF-β, ATRA could not regulate Tregs conver-
sion but retained the ability to inhibit IL-17 production
[15,16], which might be the possible explanation for
the finding.
The overexpression of RORγt and RORα is characterized
in the differentiation of Th17 cells [31,32]. RORγt has been
proposed as a ‘master regulator’ for Th17 differentiation,
while RORα seems to synergize with RORγt to promote
Th17 differentiation. It has been demonstrated that coex-
pression of RORγt and RORα synergistically enhances the
number of IL-17-producing cells [31]. However, this study
found that the combined administration of ATRA and
TGF-β inhibits the expression of RORγt rather than RORα,
especially in the allograft. Taking into consideration that
RORα is not the major player in the induction of Th17
cells and that ATRA might regulate Th17 differentiation
through other mechanisms [23,33], the exact effect of
ATRA on RORα merits further investigation.
Our results showed an elevated level of IL-17 in
the aqueous humor at 4wks and 8wks postoperative.
Accordingly, a slit lamp and a histological examination at
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fibrous tissue proliferation. IL-17, the key cytokine
produced by Th17 cells, has been proven to recruit
monocytes and neutrophils, promote angiogenesis [34],
and stimulate the proliferation of fibroblasts [35]. Many
studies have confirmed that IL-17 is involved in allograft
rejection, and neutralization of IL-17 inhibits accelerated
allograft rejection. In contrast, IL-10, one of the most
important immunosuppressive cytokines secreted by
Tregs, has been proven to favor allograft acceptance and
has a close relationship with the allograft’s function
[36,37]. Various studies have reported that after solid
organ transplantation, an elevated content of IL-10 was
found among patients with grafts accepted or without
acute rejection episodes [36,37], confirming its immuno-
modulatory effects. The combined treatment of ATRA
and TGF-β could promote IL-10 levels in the serum and
aqueous humor and reduce IL-17 expression simultan-
eously, and changes of these cytokines are consistent with
the prognosis of cornea grafts. Combining our results and
previous findings, we deduce that although reducing the
Th17 generation and manipulating host inflammation
may well be beneficial for the outcome of allograft, foster-
ing regulatory-type alloimmunity is also essential to
achieve lasting transplant tolerance and improve function
posttransplant. Nevertheless, the statistical differences for
the level of IL-10 are very small in this research and may
not be biologically important. The exact role of IL-10 in
modulating immunological reaction toward allogeneic
corneal grafts merits further studies.
Apart from the effect on the Treg-Th17 axis, another
beneficial outcome of ATRA to graft survival should also
be taken into consideration. It has been shown that the
recovery of corneal epithelial cells is important to graft
survival after corneal transplantation. Delayed epithelium
recovery or persistent epithelial defect would hamper or
even be detrimental to graft survival [38]. ATRA has been
shown to promote corneal epithelium wound healing [39].
This study found that either single administration of
ATRA or combined treatment of ATRA +TGF-β could
improve graft survival at early time point after trans-
plantation, indicating that the beneficial effect of ATRA to
corneal epithelium recovery might also play an important
role in promoting graft survival.
Conclusions
In brief, with the presence of TGF-β, the administration
of ATRA not only promoted graft survival in recipient
mice after allogeneic penetrating keratoplasty, but also
simultaneously expanded the CD4 +CD25 + Foxp3+ Tregs
and reduced the population of Th17 cells in the peripheral
blood, spleen and draining lymph nodes. Our findings sug-
gest that the combined application of ATRA and TGF-β
may shift the Th17-Treg balance toward Tregs, hencefacilitating the induction of immunological tolerance after
allogenic corneal transplantation and representing a poten-




Male BALB/c (H-2d) and C57BL/6 (H-2b) mice (weighing
20-24 g, 6-8-weeks-old) were purchased from the
Department of Laboratory Animal Science, Fudan
University. All mice were housed in a specific pathogen-
free (SPF) environment. All experimental manipulations
were undertaken in accordance with the Institutional
Guidelines for the Care and Use of Laboratory Animals
(Additional file 1) and ARVO Statement for the Use of
Animals in Ophthalmic and Vision Research.
Orthotopic corneal transplantation (penetrating
keratoplasty)
The surgical procedure was performed as previously
reported [19]. In brief, C57BL/6 mice were sacrificed by
cervical dislocation and a 2-mm-diameter trephine was
used to obtain the cornea as the donor of allogenic
penetrating keratoplasty. BALB/c mice, with the right
eyes serving as the recipients, were anesthetized with
100 mg/Kg of ketamine hydrochloride and 5 mg/Kg of
diazepam. After dilating the pupil by administering
0.25% tropicamide eye drops, a 1.5-mm-diameter trephine
was used to cut the recipient cornea at the depth of
80-90%, and then paracentesis was carefully done with
a 1 ml needle to avoid damaging the lens. Viscoelastic
material containing 3% sodium hyaluronate (Healon,
Advanced Medical Optics, Santa Ana, CA) was injected
immediately to maintain the anterior chamber. Then, the
recipient cornea was cut with scissors and the donor cor-
nea was fixed to the recipient’s bed with eight interrupted
11–0 nylon sutures. Erythromycin eye ointment was
administered in the conjunctival sac after the surgery, and
then the eyelids were sutured with an 8–0 mattress
sutures. The eyelids sutures were removed at day 3 post-
operatively and the corneal sutures were removed 7 days
after surgery. Simultaneously, the syngeneic penetrating
keratoplasty was performed from BALB/c to BALB/c
mice, using the completely same surgical procedure.
Post-transplant therapies
A total of 120 mice underwent allogeneic penetrating
keratoplasty, and the recipient mice were randomly
divided into four groups, each containing 30 mice.
Group A was intraperitoneally administered with ATRA
(Sigma-Aldrich) at a dose of 3 mg/kg/day, which was dis-
solved in dimethyl sulfoxide (DMSO). Group B was intra-
peritoneally treated with TGF-β 5 μg/kg/day (PreproTech,
NJ, USA). The combined treatment of ATRA 3 mg/kg/day
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recipient mice in group D received an equivalent volume of
vehicle as control. Group E contained another 30 syngeneic
graft recipient mice, which didn’t receive any treatment. If
mice were dead during the follow-up, we would recruit the
same number of recipient mice to assure that at least 10
mice in each group could be sacrificed for further in vitro
experiments at 2wks, 4wks and 8wks after surgery.
Assessment of the grafts
All recipient mice were examined under the slitlamp
biomicroscope two times a week after surgery, and digital
photographs of the cornea were taken using a Canon 8-
megapixel digital camera attached to the slitlamp biomi-
croscope. The transparency of the graft and the formation
of neovascularization in the graft and host tissue were re-
corded and scored to assess the degree of graft rejection
according to the previous literature [40]. Mice with infec-
tion, hyphema and cataract were excluded.
Flow cytometric analysis
FITC-, APC- or PE-conjugated antibodies specific for
mouse CD4 (RM4-5), CD25 (PC61.5), Foxp3 (FJK-16 s),
CD3e (145-2C11), CD8a (53–6.7), IL-17 (TC11-18H10.1),
and their isotype controls were purchased from eBioscience,
or BioLegend (San Diego, CA, USA).
At 2wks, 4wks and 8wks after surgery, four recipient mice
in each group were sacrificed and the peripheral blood was
collected in heperanized tubes. Meanwhile, the spleen and
draining lymph nodes were obtained. Single cell suspension
of the spleen and lymph nodes was prepared by compres-
sion with the plunger of a 3 ml syringe. After that, the cells
were centrifuged and resuspended in an appropriate volume
of flow cytometry staining buffer so as to adjust the final cell
concentration to 2x107/mL. Each sample was then divided
into two parts. One was incubated with anti-mouse CD4
and CD25 mAb for at least 30 min at 4°C in the dark, and
then washed, fixed, permeabilized and stained with anti-
mouse Foxp3 mAb for another 30 min at 4°C in the dark.
The other part was stimulated with 0.1 μg/mL PMA
(Sigma), 1 μg/mL ionomycin (Sigma) and monensin (Golgi-
Stop, 1 μl/ml; BD Biosciences) for 4 hrs at 37°C. Following
that, it was incubated with anti-mouse CD3 and CD8
mAb for at least 30 min at 4°C in the dark and then
washed, fixed, permeabilized and stained with anti-mouse
IL-17 mAb for another 30 min at 4°C in the dark. Finally,
the cells were resuspended with a flow cytometry
staining buffer, and analyzed using an FACS Calibar
flow cytometer (Becton Dickinson, San Jose, CA) and
CellQuest software.
Histology assessment
At 2wks, 4wks and 8wks after surgery, three recipient mice
in each group were sacrificed. The eyeballs were enucleatedand fixed in the mixture of 40% formaldehyde, 40% glacial
acetic acid and 95% ethanol for 24 hrs and then dehydrated
in graded ethanol solutions and embedded in paraffin wax.
The embedded tissue was cut to 4–6 micron-thick
sections. The sections for histological examination
underwent routine hematoxylin eosin staining and were
studied under light microscopy (Nikon, ALPHAPHOTO-2
YS2, Japan). The quantitative analysis of infiltrated inflam-
matory cells was performed by a masked observer using
software ImageJ (http://rsb.info.nih.gov/ij/download.html).
Immunofluorescence staining
To perform immunofluorescence staining, the sections
were firstly deparaffinized in xylenes using three changes
for 5 min each and then hydrated gradually through
graded alcohols: wash in 100% ethanol twice for 10 min
each and then 95% ethanol twice for 10 min each. Anti-
gen retrieval was performed by heating the slides in
10 mM sodium citrate buffer, pH 6.0, at 95°C for 5 min
and then cooling them in the buffer for approximately
20 min until they reached room temperature. Afterward,
the slices were washed with PBS three times and the
excess liquid was aspirated. After several blocking steps,
the sections were incubated with 1:100 rabbit anti-
mouse Foxp3 mAb (H-190, Santa Cruz Biotechnology,
Inc., Santa Cruz, CA) and 1:100 rat anti-mouse IL-17
mAb (TC11-18H10, Santa Cruz) at 37°C for 1 hr and
then at 4°C overnight. The slices were washed with PBS
three times for 5 min each and then incubated with
Alexa Fluor 546 donkey anti-rabbit IgG (Invitrogen,
CA, USA) and Alexa Fluor 488 rabbit anti-rat IgG
(Invitrogen) for 2 hrs. Finally, the sections were
mounted with glycerol and examined under laser scanning
confocal microscopy (TCS SP2, Leica, Germany). The
quantitative analysis of Foxp3+ cells and IL-17+ cells was
also performed as mentioned above.
Real-time PCR of Foxp3, RORγt and RORα in the grafts
and PBMCs
At 2wks, 4wks and 8wks after surgery, three recipient
mice in each group were sacrificed. PBMCs were isolated
on Ficoll-Hypaque density gradients (GE Healthcare
Bio-Sciences Corp., Piscataway, NJ). Cells recovered
from the gradient interface were washed twice in PBS
and then collected. Meanwhile, the eyeballs were enucleated
and the cornea was harvested from the limbus. The gene
expression of Foxp3, RORγt and RORα in the cornea tissue
and PBMCs was analyzed using quantitative real-time PCR.
Total RNA was extracted from homogenized harvested
cornea grafts using the Qiagen RNeasy mini Kit (Qiagen,
Tokyo, Japan), according to the manufacturer’s instructions.
Reverse transcription to cDNA was performed using
Taqman reverse transcription reagents (Applied Biosystems,
USA). The sequences of forward and reverse primer for
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5′ TCCTCTTCTTGCGAAACTCA 3′, respectively. The
sequences for RORγt gene were 5′ CAGGAGCAATGGAA
GTCGTC 3′ and 5′ CCGTGTAGAGGGCAATCTCA 3′.
Those for RORα were 5′ GCTGTGTGCCATCAAGAT
TAC 3′ and 5′ CACGGTGTTGTTCTGAGAGTC 3′.
Mouse β-actin was used as an endogenous control.
Relative quantification assays for gene expression of
Foxp3, RORγt and RORα were performed using a
StepOnePlus real-time PCR system (Applied Biosystem,
USA). For each example, the threshold cycle (CT)
value of the target gene was normalized using the for-
mula △CT =CTtarget gene-CTβ-actin. △△CT of each target
gene was further calculated by the formula △CTtreated
group-△CTsyngeneic group. The mean △△CT was determined
and the relative mRNA expression of Foxp3, RORγt and
RORα was calculated with 2-△△CT.
ELISA
The peripheral blood was collected under ethyl ether
inhalation anesthesia, and the aqueous humor was
obtained with capillary glass tube right after the sacrifice
of recipient mice. An enzyme-linked immunosorbent
assay was performed to test the expression of IL-10 and
IL-17 in the serum and aqueous humor, using ELISA
kits (M1000 and M1700, R&D System, MN, USA).
Immunosuppressive assay
The immunosuppressive activity of CD4 + CD25 + Foxp3
+ Tregs was determined by the suppression of a mixed
lymphocyte reaction (MLR). Splenocytes (1 × 105/well)
from naive BALB/c mice were either cultured alone as a
negative control group or cocultured with mitomycin
(25 mg/L)-pretreated splenocytes (1 × 105/well) from
C57BL/6 as a positive control group. The CD4 +CD25 +
Foxp3+ Tregs were isolated by MACS with a CD4 +CD25+
Regulatory T Cell Isolation Kit (Miltenyi Biotec, Germany)
from recipient mice treated with ATRA, TGF-β, ATRA+
TGF-β or a control solution. Isolated Tregs (0.5 × 105/well)
were either added to the coculture system and cultured for
3 days as the experimental group or cultured alone as a
blank control group. A non-radioactive cell proliferation
assay (G4000, Promega, WI, USA) was used to determine
the cell proliferation activity, according to the manufac-
turer’s instructions. The absorbance at 570 nm (A
value) was recorded by a microtiter plate reader. The
suppressive rate was calculated as: suppressive rate =
[1 − (Aexperimental group − Ablank control group − Anegative
control group)/ (Apositive control group −Anegative control group)] ×
100 %.
Statistical analysis
Data are presented as the mean ± SD. Statistical signifi-
cance was determined using One-way analysis of variance(ANOVA), Student’s t-test or Kruskal-Wallis test. For each
ANOVA, post-hoc Fisher PLSD (protected least significant
difference) was performed to determine each individual
group difference. A Kaplan-Meier survival curve and
Log-rank statistical analysis were used to compare the
graft survival rate among the five groups. All tests
were considered statistically significant at P <0.05 (SPSS
for Windows, version 13.0; SPSS, Inc., Chicago, IL).
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